Lemaitre Vascular (LMAT) AI Stock Analysis

• Market Cap: $1.95B
• Dividend Yield: 0.88%
• Average Volume (3M): 131.07K
• Price to Earnings (P/E): 41.9
• Beta (1Y): 0.86
• Revenue Growth: 13.07%
• EPS Growth: 27.98%
• Country: US
• Employees: 651
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.75
• Shares Outstanding: 22,637,522
• 10 Day Avg. Volume: 144,773
• 30 Day Avg. Volume: 131,073
• PEG Ratio: 1.06
• Price to Book (P/B): 6.13
• Price to Sales (P/S): 9.41
• P/FCF Ratio: 55.67
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $98.75
• Price Target Upside: 13.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: $98.00 ▲(12.31% Upside)

Lemaitre Vascular's overall stock score reflects strong financial performance and a balanced earnings outlook, despite technical indicators suggesting a bearish trend and a high valuation. The company's robust profitability and effective cost management are significant strengths, while challenges in the APAC market and a recent FDA warning letter present risks.

Positive Factors

Strong Organic Sales Growth

The 12% organic sales growth, led by Grafts and Shunts, indicates robust demand and effective market penetration, supporting long-term revenue expansion.

Robust Cash Flow and Financial Position

Strong cash reserves and cash generation enhance financial flexibility, enabling strategic investments and cushioning against economic downturns.

European Regulatory Approvals

Regulatory approvals in Europe facilitate international expansion, increasing market reach and potential revenue streams in new regions.

Negative Factors

FDA Warning Letter

The FDA warning letter could lead to increased scrutiny and operational adjustments, potentially impacting production efficiency and compliance costs.

Challenges in Asia Pacific Market

Struggles in APAC, due to management changes, may hinder growth prospects and require strategic realignment to improve regional performance.

Lowered Revenue Guidance

Lowered revenue guidance reflects external pressures like FX changes, which could affect profitability and necessitate cost management strategies.

Lemaitre Vascular Business Overview & Revenue Model

Company Description

Lemaitre Vascular (LMAT) is a medical device company that specializes in the development, manufacturing, and marketing of products for the treatment of vascular diseases. The company primarily focuses on peripheral vascular surgery and offers a range of products including vascular grafts, stent grafts, and other related surgical devices. With a commitment to innovation, Lemaitre Vascular aims to improve patient outcomes through its advanced technologies and products designed for the treatment of various vascular conditions.

How the Company Makes Money

Lemaitre Vascular generates revenue primarily through the sale of its medical devices and products used in vascular surgery. Key revenue streams include direct sales of vascular grafts and stent grafts to hospitals and surgical centers, as well as recurring revenues from the sale of consumables associated with these procedures. The company also benefits from strategic partnerships with healthcare providers and distributors, which expand its market reach and enhance its sales capabilities. Additionally, Lemaitre Vascular invests in research and development to introduce new products, driving future growth and revenue potential.

Lemaitre Vascular Financial Statement Overview

Summary

Lemaitre Vascular exhibits strong financial health with robust profitability, a stable balance sheet, and solid cash flow generation. The company is well-positioned in the medical instruments and supplies industry, with consistent revenue growth and effective cost management. While the increase in debt requires attention, the company's financial metrics suggest a positive outlook.

Income Statement

Lemaitre Vascular demonstrates strong profitability with a consistent increase in gross profit margin, reaching 70.97% in TTM. The net profit margin has also improved to 22.14%, indicating effective cost management. Revenue growth is steady at 2.65% in TTM, showing resilience in a competitive market. However, the EBIT margin has slightly decreased, suggesting potential pressure on operating efficiency.

Balance Sheet

The company's balance sheet is robust, with a manageable debt-to-equity ratio of 0.49 in TTM, reflecting prudent financial leverage. Return on equity has improved to 14.96%, indicating efficient use of shareholder funds. The equity ratio remains strong, underscoring financial stability. However, the increase in total debt warrants monitoring.

Cash Flow

Cash flow performance is solid, with a significant free cash flow growth rate of 26.58% in TTM, highlighting strong cash generation capabilities. The operating cash flow to net income ratio of 2.20 indicates healthy cash conversion. The free cash flow to net income ratio of 0.90 suggests effective cash management, though maintaining this trajectory is crucial.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	240.87M	219.86M	193.48M	161.65M	154.42M	129.37M
Gross Profit	170.94M	150.90M	127.05M	104.90M	101.38M	84.62M
EBITDA	80.57M	66.75M	48.99M	36.92M	45.98M	36.89M
Net Income	53.34M	44.04M	30.11M	20.64M	26.91M	21.22M
Balance Sheet
Total Assets	598.07M	551.82M	346.78M	310.48M	292.80M	252.81M
Cash, Cash Equivalents and Short-Term Investments	343.06M	299.72M	105.07M	82.69M	69.96M	26.98M
Total Debt	185.63M	185.69M	19.09M	16.60M	15.94M	54.78M
Total Liabilities	219.15M	214.53M	48.88M	42.27M	38.65M	80.24M
Stockholders Equity	378.92M	337.29M	297.90M	268.20M	254.15M	172.57M
Cash Flow
Free Cash Flow	66.23M	37.16M	29.49M	22.15M	30.22M	31.82M
Operating Cash Flow	73.28M	44.12M	36.75M	25.38M	35.10M	34.80M
Investing Cash Flow	-222.01M	-200.12M	-24.71M	-10.37M	-61.08M	-52.89M
Financing Cash Flow	153.13M	158.10M	-7.13M	-9.23M	13.70M	32.16M

Lemaitre Vascular Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 87.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LMAT, the sentiment is Negative. The current price of 87.26 is below the 20-day moving average (MA) of 87.80, below the 50-day MA of 89.58, and below the 200-day MA of 87.73, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 44.89 is Neutral, neither overbought nor oversold. The STOCH value of 35.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LMAT.

Lemaitre Vascular Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	75 Outperform	$1.95B	41.90	15.02%	0.88%	13.07%	27.98%
ATRC	65 Neutral	$1.59B	―	-6.11%	―	15.80%	26.94%
ANGO	61 Neutral	$495.22M	―	-17.10%	―	2.73%	87.03%
BLFS	54 Neutral	$1.25B	―	-5.20%	―	-18.82%	92.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	50 Neutral	$1.32B	―	-24.65%	―	-32.42%	-540.37%
OSUR	44 Neutral	$171.80M	―	-15.30%	―	-43.95%	-620.21%

Lemaitre Vascular Corporate Events

LeMaitre Vascular’s Earnings Call: Growth Amid Challenges

LeMaitre Vascular’s recent earnings call painted a balanced picture of the company’s current standing and future prospects. The call highlighted strong organic sales growth and international expansion, alongside challenges such as a catheter recall and lowered revenue guidance due to foreign exchange fluctuations. The sentiment conveyed was one of cautious optimism, acknowledging both achievements and hurdles.

LeMaitre Vascular Reports Strong Q3 2025 Financial Growth

LeMaitre Vascular, Inc., a company specializing in the development, manufacturing, and marketing of vascular devices and implants, operates within the medical device industry, focusing on solutions for peripheral vascular disease.